Osteoporosis Drugs Market Growth, Segment, Progress, Trends, and Global Forecast 2027

Comments · 181 Views

The global osteoporosis market is currently eyeing for a staggering USD 14,300 million valuation during the forecast period (2013-2022), claims Market Research Future (MRFR) in a detailed study.

Overview:

The global osteoporosis market is currently eyeing for a staggering USD 14,300 million valuation during the forecast period (2013-2022), claims Market Research Future (MRFR) in a detailed study. Booming urbanization and technological advancements may have a lot to do with the progressing world, but they have some adverse effects too. Osteoporosis is one such side-effect of the fast-evolving lifestyle and the inflating osteoporosis drugs market is a direct result of that. The market is about to witness a moderate CAGR of 4.7% during the forecast period. 

Drivers and Restraints:

Osteoporosis follows a genetic map in targeting people. The Caucasians are more susceptible to osteoporosis, and the Asians come next. Whereas, the Africans are the least in number to suffer from this disease. Along with this gender bias, a rise in geriatric population, alcoholism and smoking, the prevalence of various disease such as cancer, autoimmune disorders, thalassemia, hormonal and disorders are also affecting the bone condition of the mass. 

Adoption of a sedentary lifestyle triggered by work-related pressures and technological advancements is also one of the chief driving force for the osteoporosis drug market growth. Furthermore, women are more prone to this disease. This has given rise to awareness and technological and medical awareness which also giving the market a much-needed thrust.

Market Dashboard:

The market is mainly getting driven by mergers and acquisitions. For instance, Novartis has recently acquired AveXis, Inc. On the other hand, F. Hoffmann La Roche Ltd. reached an agreement with Foundation Medicine regarding a definitive merger.  

Some of the key players in this market are Eli Lilly and Company, Merck Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others. 

Segmentation:

The global market for osteoporosis drug market can be segmented by drug class, route of administration and gender.

By osteoporosis medications, the market can be segmented into bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. Bisphosphonates are currently leading the market. The drug is the most commonly prescribed medicine resulting in the medicine capturing almost half of the market.

On the basis of route of administration, the market comprises oral, injectable and others.  

Based on gender, the market comprises male and female. However, women are more prone to this disease. As per the studies of the International Osteoporosis Foundation (IOF), worldwide over a billion women are now suffering from the disease. 

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013,

United States of America

Comments